» Articles » PMID: 35959292

Alzheimer-Compound Identification Based on Data Fusion and ForgeNet_SVM

Overview
Specialty Geriatrics
Date 2022 Aug 12
PMID 35959292
Authors
Affiliations
Soon will be listed here.
Abstract

Rapid screening and identification of potential candidate compounds are very important to understand the mechanism of drugs for the treatment of Alzheimer's disease (AD) and greatly promote the development of new drugs. In order to greatly improve the success rate of screening and reduce the cost and workload of research and development, this study proposes a novel Alzheimer-related compound identification algorithm namely forgeNet_SVM. First, Alzheimer related and unrelated compounds are collected using the data mining method from the literature databases. Three molecular descriptors (ECFP6, MACCS, and RDKit) are utilized to obtain the feature sets of compounds, which are fused into the all_feature set. The all_feature set is input to forgeNet_SVM, in which forgeNet is utilized to provide the importance of each feature and select the important features for feature extraction. The selected features are input to support vector machines (SVM) algorithm to identify the new compounds in Traditional Chinese Medicine (TCM) prescription. The experiment results show that the selected feature set performs better than the all_feature set and three single feature sets (ECFP6, MACCS, and RDKit). The performances of TPR, FPR, Precision, Specificity, F1, and AUC reveal that forgeNet_SVM could identify more accurately Alzheimer-related compounds than other classical classifiers.

Citing Articles

Machine learning in TCM with natural products and molecules: current status and future perspectives.

Ma S, Liu J, Li W, Liu Y, Hui X, Qu P Chin Med. 2023; 18(1):43.

PMID: 37076902 PMC: 10116715. DOI: 10.1186/s13020-023-00741-9.

References
1.
Dong H, Csernansky C, Martin M, Bertchume A, Vallera D, Csernansky J . Acetylcholinesterase inhibitors ameliorate behavioral deficits in the Tg2576 mouse model of Alzheimer's disease. Psychopharmacology (Berl). 2005; 181(1):145-52. PMC: 1361685. DOI: 10.1007/s00213-005-2230-6. View

2.
Mehta K, Ott A, Kalmijn S, Slooter A, van Duijn C, Hofman A . Head trauma and risk of dementia and Alzheimer's disease: The Rotterdam Study. Neurology. 1999; 53(9):1959-62. DOI: 10.1212/wnl.53.9.1959. View

3.
An H, Huang D, Yang H, Liu X, Du J, Li Y . Comprehensive chemical profiling of Jia-Wei-Qi-Fu-Yin and its network pharmacology-based analysis on Alzheimer's disease. J Pharm Biomed Anal. 2020; 189:113467. DOI: 10.1016/j.jpba.2020.113467. View

4.
Pang X, Wang Z, Fang J, Lian W, Zhao Y, Kang D . [Network pharmacology study of effective constituents of traditional Chinese medicine for Alzheimer’s disease treatment]. Yao Xue Xue Bao. 2018; 51(5):725-31. View

5.
Takada-Takatori Y, Kume T, Sugimoto M, Katsuki H, Sugimoto H, Akaike A . Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology. 2006; 51(3):474-86. DOI: 10.1016/j.neuropharm.2006.04.007. View